Table 3.
Extraglandular manifestations in patients with juvenile Sjögren's syndromea
| No. | SGUS– | SGUS+ | P b | Benjamin‐Hochberg adjustment | |
|---|---|---|---|---|---|
| Extraglandular manifestations | 56/62 (90)c | 24/25 (96) | 32/37 (86) | 0.214 | NS |
| Constitutional | 24/59 (41)d | 12/25 (48) | 12/34 (35) | 0.326 | NS |
| Cutaneous | 17/59 (29)e | 8/25 (32) | 9/34 (26) | 0.643 | NS |
| Lymphadenopathy | 35/59 (59)f | 17/25 (68) | 18/34 (53) | 0.245 | NS |
| Articular | 34/59 (58)g | 17/25 (68) | 17/34 (50) | 0.167 | NS |
| Muscular | 5/59 (8) | 1/25 (4) | 4/34 (12) | 0.290 | NS |
| Pulmonary | 1/59 (2) | 1/25 (4) | 0/34 (0) | 0.240 | NS |
| Renal | 3/59 (5)h | 1/25 (4) | 2/34 (6) | 0.745 | NS |
| Peripheral nervous system | 1/59 (2) | 1/25 (4) | 0/34 (0) | 0.240 | NS |
| Central nervous system | 3/59 (5) | 3/25 (12) | 0/34 (0) | 0.038 | NS |
| Hematologic domain | 16/58 (28)e | 6/24 (25) | 10/34 (29) | 0.711 | NS |
| Biologic domain | 21/58 (36)i | 9/24 (38) | 12/34 (35) | 0.863 | NS |
| ESSPRI score, mean ± SD |
3.5 ± 2.5 (n = 65) |
3.2 ± 2.8 | 3.7 ± 2.3 | 0.368 | NS |
| ESSPRI dryness, mean ± SD |
3.4 ± 3.0 (n = 65) |
3.4 ± 2.9 | 3.5 ± 3.1 | 0.919 | NS |
| ESSPRI fatigue, mean ± SD |
4.3 ± 3.4 (n = 65)j |
3.8 ± 3.9 | 4.6 ± 3.0 | 0.314 | NS |
| ESSPRI pain, mean ± SD |
2.9 ± 3.2 (n = 65) |
2.4 ± 3.4 | 3.2 ± 3.2 | 0.362 | NS |
| Total ESSDAI score, mean ± SD |
4.7 ± 5.4 (n = 62) |
3.4 ± 2.8 | 5.5 ± 6.5 | 0.138 | NS |
| Clinical ESSDAI, mean ± SD |
3.2 ± 4.1 (n = 59) |
2.7 ± 3.0 | 3.6 ± 4.8 | 0.443 | NS |
Values are the number of patients with positive findings/patients with available information (%), unless indicated otherwise. Regional differences refer to patients included in Brazil compared to patients included in Europe/US. SGUS = salivary gland ultrasonography; NS = nonsignificant; ESSPRI = European League Against Rheumatism (EULAR) Sjögren's Syndrome Patients Reported Index; ESSDAI = EULAR Primary Sjögren's Syndrome Disease Activity Index.
P values are for the comparison of SGUS+ and SGUS– patients.
Eight patients with systemic lupus erythematosus (SLE)/mixed connective tissue disease (MCTD), with regional differences.
Five patients with SLE/MCTD, with regional differences.
¶Five patients with SLE/MCTD.
Three patients with SLE/MCTD, with regional differences.
Eight patients with SLE/MCTD.
Three patients with SLE/MCTD.
Six patients with SLE/MCTD.
Regional differences.